Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTIMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	10551985				
	2005-10-04				
Bamfe	Bamford				
	1625				
Aulakh					
er	PB60199USw				

U.S.PATENTS							Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear			
/CA/	1	4166853		1979-09	I-04	McCall					
/CA/	2	5789596		1998-08	i-04	Brieden et al.					
/CA/	3	5998518		1999-12	:-07	Steinmann					
If you wis	If you wish to add additional U.S. Patent citation information please click the Add button.										
	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	nd Publication ode1 Date		Name of Pate of cited Docu	entee or Applicant ment	Relev		Lines where ges or Relev	
/CA/	1	20040082544	A1	2004-04	-29	Greco et al.					
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² j Code ⁴		Publication Date	Name of Patentee or Applicant of cited Document		where Rel	or Relevant	T5	
/CA/	1	9300313	wo		A2	1993-01-07	Virginia Commonwe University	ealth			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551985				
Filing Date		2005-10-04				
First Named Inventor	Bamfe	Bamford				
Art Unit		1625				
Examiner Name	Aulakh					
Attorney Docket Number		DR60100LISW				

	-				1	r r	7	
/CA/	2	0206196	wo	A1	2002-01-24	Merck Patent GmbH		
/CA/	3	03035654	wo	A1	2003-05-01	Ortho-McNeil Pharmaceutical, Inc.		
/CA/	4	0318029	EP	B1	1989-05-31	Eisai Co., Ltd.		
/CA/	5	0548798	EP	A1	1993-06-30	Sanwa Kagaku Kenkyusho Co., Ltd.		
/CA/	6	0607536	EP	B1	1994-07-27	SS Pharmaceutical Co., Ltd.		
/CA/	7	9500131	wo	A1	1995-01-05	Cambridge Neuroscience, Incorporated		
/CA/	8	9517385	wo	A1	1995-06-29	Ortho Pharmaceutical Corporation		
/CA/	9	9312986	wo	A1	1993-07-08	C.R.E.C.A.		
If you wis	h to ac	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button Add		
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner linitials* No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
/CA/	"Crystallization"; Kirk-Othmer Encyclopedia of Chemical Technology, 2002; Vol. 8; pp. 95-147;							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551985			
iling Date		2005-10-04			
irst Named Inventor	Bamfe	Bamford			
Art Unit		1625			
Examiner Name	Aulakh				
Attorney Docket Number		PR60199LISW			

/CA/	2	IZQUIERDO ET AL.; "Rupatadine: A New Selective Histamine H1 Receptor and Platelet-Activating Factor (PAF) Antagonist"; CA 139:301165; 2003;							
/CA/	3	SIMPSON ET AL.; "Fexofenadine: A Review of Its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria"; CA 132-231383; 2000;							
/CA/	4	BRAGA ET AL.; "Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism"; Chem. Commun.; 2005; pp. 3635-3645;							
/CA/	5	FLAMAND ET AL.; "Histamine-Induced Inhibition of Leukotriene Biosynthesis in Human Neutrophils: Involvement of the H2 Receptor and cAMP"; Br. J. Pharm.; 2004; Vol. 141; pp. 552-561;							
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature /Charaniit Aulakh/ Date Considered 10/13/2009									

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.